Ozempic vs. Qsymia
Ozempic and Qsymia differ significantly in mechanism and indications. Ozempic is a GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction, while Qsymia combines phentermine and topiramate for chronic weight management. Ozempic achieves HbA1c reductions and moderate weight loss, while Qsymia delivers more notable weight-loss results, albeit without the glucose benefits. Qsymia’s stimulant component increases risks of mood changes and insomnia, unlike Ozempic’s primary side effects of nausea and vomiting. Ozempic costs $875/month, much higher than Qsymia’s $300/month. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Phentermine suppresses appetite by stimulating the release of norepinephrine in the brain; topiramate enhances feelings of fullness and alters taste perceptions, reducing food intake.
Common Side Effects
Dry mouth, insomnia, constipation, dizziness, and tingling in hands or feet.
Serious Potential Side Effects
Increased heart rate, mood changes, suicidal thoughts, and memory/concentration difficulties, dependency and abuse of medication